Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
Sam Mayes,1 Adam Gibb,1 Tim Illidge1,21The Christie Hospital NHS Foundation, Wilmslow Road, 2School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Sciences Centre, UKAbstract: Treatment of primary refractory and relapsed classical Hodgkin lymphoma remains chall...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-05-01
|
| Series: | Blood and Lymphatic Cancer: Targets and Therapy |
| Online Access: | http://www.dovepress.com/profile-of-brentuximab-vedotin-and-its-potential-in-the-treatment-of-r-a9940 |